KRON (Kronos Bio) Margin of Safety % (DCF FCF Based) : N/A (As of Mar. 28, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Kronos Bio Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Kronos Bio's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Kronos Bio's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Kronos Bio's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kronos Bio's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kronos Bio's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Kronos Bio's Margin of Safety % (DCF FCF Based) falls into.

Save Embed

;

Save Embed

;

Kronos Bio Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Kronos Bio's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Kronos Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kronos Bio Inc (NAS:KRON) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1300 So. El Camino Real, Suite 400, San Mateo, CA, USA, 94402

Website

https://www.kronosbio.com

Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.

Executives

Norbert W Bischofberger	director, 10 percent owner, officer: President & CEO	333 LAKESIDE DR, C/O GILEAD SCIENCES, INC., FOSTER CITY CA 94404
Jorge Dimartino	officer: Chief Medical Officer & VP	C/O KRONOS BIO, INC., 1300 S, SAN MATEO CA 94402
Christopher Dinsmore	officer: Chief Scientific Officer	C/O KRONOS BIO, INC., 1300 EL CAMINO REAL, STE. 300, SAN MATEO CA 94402
Barbara Kosacz	officer: COO & General Counsel	3175 HANOVER STREET, PALO ALTO CA 94304
Sandra A. Gardiner	officer: Interim CFO	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Yasir B. Al-wakeel	officer: Chief Financial Officer	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Roger D Dansey	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Katherine V Stultz	director	C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Backer Marianne De	director	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Roshawn A. Blunt	director	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jakob Loven	director	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Taiyin Yang	director	2631 HANOVER STREET, PALO ALTO CA 94304
Otello Stampacchia	director, 10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
John C Martin	director	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Elena Ridloff	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130